Kivu Bioscience raised $92 million in a Series A led by Novo Holdings to advance multiple oncology programs into the clinic.

Oct 28, 2024•10 months ago

Amount Raised

$92 Million

Round Type

series a

San FranciscoBiotechnologyHealth Care

Investors

Brabantse Ontwikkelings Maatschappij (Bom)M VenturesBio Generation VenturesHealth CapRed Tree Venture CapitalGimvNovo Holdings

Description

Kivu Bioscience has successfully closed a $92 million Series A financing round, led by Novo Holdings alongside various other investors. The funds will be utilized to push their next-generation antibody-drug conjugates into clinical development, aiming for safer and more effective cancer treatments.

Company Information

Company

Kivu Bioscience

Location

San Francisco, California, United States

About

Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. Kivu is advancing its first two lead candidates to clinical trials expected to begin in 2025.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech